Renaissance Technologies LLC Has $1.36 Million Stock Position in OptimizeRx Corp. $OPRX

Renaissance Technologies LLC increased its stake in OptimizeRx Corp. (NASDAQ:OPRX) by 633.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 216,856 shares of the company’s stock after purchasing an additional 187,278 shares during the quarter. Renaissance Technologies LLC owned approximately 1.16% of OptimizeRx worth $1,362,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Rhumbline Advisers boosted its position in shares of OptimizeRx by 29.9% in the second quarter. Rhumbline Advisers now owns 36,082 shares of the company’s stock worth $487,000 after buying an additional 8,297 shares during the period. American Century Companies Inc. grew its holdings in shares of OptimizeRx by 52.5% during the second quarter. American Century Companies Inc. now owns 24,069 shares of the company’s stock valued at $325,000 after buying an additional 8,286 shares in the last quarter. Russell Investments Group Ltd. raised its position in OptimizeRx by 141.4% during the second quarter. Russell Investments Group Ltd. now owns 110,610 shares of the company’s stock valued at $1,493,000 after buying an additional 64,790 shares during the period. Quantbot Technologies LP acquired a new position in OptimizeRx during the second quarter valued at $44,000. Finally, WINTON GROUP Ltd purchased a new stake in OptimizeRx in the 2nd quarter worth about $286,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Price Performance

OPRX opened at $8.78 on Friday. The stock has a fifty day moving average price of $6.04 and a 200 day moving average price of $6.72. The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.16. OptimizeRx Corp. has a 1 year low of $4.54 and a 1 year high of $22.25. The stock has a market cap of $164.71 million, a price-to-earnings ratio of 38.18 and a beta of 1.08.

OptimizeRx (NASDAQ:OPRX) last issued its earnings results on Wednesday, August 12th. The company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.05. OptimizeRx had a return on equity of 9.52% and a net margin of 4.66%.The company had revenue of $20.50 million for the quarter, compared to analyst estimates of $20.20 million. Analysts forecast that OptimizeRx Corp. will post 0.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on OPRX shares. Stephens lowered their target price on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 13th. Lake Street Capital reduced their price target on shares of OptimizeRx from $20.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Weiss Ratings restated a “sell (d)” rating on shares of OptimizeRx in a report on Tuesday. Stifel Nicolaus set a $12.00 price objective on shares of OptimizeRx in a research report on Thursday. Finally, Wall Street Zen lowered shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $13.14.

Key OptimizeRx News

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q2 earnings and revenue topped estimates. OptimizeRx reported adjusted earnings of $0.16 per share, versus the $0.11 consensus estimate, while revenue of $20.5 million exceeded expectations of $20.2 million. OptimizeRx Corp. Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Full-year guidance was maintained. Management reaffirmed 2026 revenue guidance of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million. The revenue range is broadly consistent with the $97.5 million analyst consensus, reducing the risk of an additional near-term guidance cut. OptimizeRx Reiterates 2026 Revenue Outlook
• Positive Sentiment: Liquidity and debt terms improved. OptimizeRx completed a refinancing featuring a $35 million traditional banking facility, including a $25 million term loan and a $10 million undrawn revolver. The company has repaid $8.3 million of principal since inception, supporting financial flexibility for operations and growth. OptimizeRx Reports Second Quarter 2026 Results
• Neutral Sentiment: Finance leadership appointments were announced. The appointments are intended to support OptimizeRx’s next phase of growth, but investors may focus on execution during the transition. OptimizeRx Announces Finance Leadership Appointments
• Negative Sentiment: Revenue headwinds remain. Although revenue beat estimates, quarterly EPS declined from $0.24 a year earlier, and management continues to navigate revenue pressure. The CFO transition and reaffirmed—rather than raised—outlook may limit further upside until growth reaccelerates. OptimizeRx Q2 2026 Earnings Call Highlights

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.